A pharmacogenetic study of patients with schizophrenia from West Siberia gets insight into dopaminergic mechanisms of antipsychotic-induced hyperprolactinemia

• Main Authors: Diana Z. Osmanova (Author), Maxim B. Freidin (Author), Olga Yu. Fedorenko (Author), Ivan V. Pozhidaev (Author), Anastasiia S. Boiko (Author), Natalia M. Vyalova (Author), Vladimir V. Tiguntsev (Author), Elena G. Kornetova (Author), Anton J. M. Loonen (Author), Arkadiy V. Semke (Author), Bob Wilffert (Author), Nikolay A. Bokhan (Author), Svetlana A. Ivanova (Author)
• Format: Book
• Published: BMC, 2019-04-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

Abstract Background Hyperprolactinemia (HPRL) is a classical side effect of antipsychotic drugs primarily attributed to blockade of dopamine D2 receptors (DRD2s) on the membranes of lactotroph cells within the pituitary gland. Certain antipsychotic drugs, e.g. risperidone, are more likely to induce...